Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    25
    ...
ATC Name B/G Ingredients Dosage Form Price
C10AA07 LIPIROSE OBP 20 G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 639,925 L.L
J01MA14 AVITAR 400 G Moxifloxacin (HCl) - 400mg 400mg Tablet, film coated 913,813 L.L
M01AH05 COXIFLAM G Etoricoxib - 60mg 60mg Tablet, film coated 1,109,630 L.L
A02BC04 RABEC G Rabeprazole (sodium) - 10mg 10mg Tablet, film coated 212,327 L.L
J01MA14 AVITAR 400 G Moxifloxacin (HCl) - 400mg 400mg Tablet, film coated 651,764 L.L
L04AA37 OLUMIANT B Baricitinib - 2mg 2mg Tablet, film coated 68,053,864 L.L
M01AH05 ETOXA G Etoricoxib - 60mg 60mg Tablet, film coated 1,109,630 L.L
B03AA02 FEOSTA G Ferrous fumarate - 200mg 200mg Tablet, film coated 682,160 L.L
C10AA07 PREVAST 20-IPS G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 639,925 L.L
J01MA14 EVAFLOX G Moxifloxacin (HCl) - 400mg 400mg Tablet, film coated 669,234 L.L
L04AA37 OLUMIANT B Baricitinib - 4mg 4mg Tablet, film coated 68,053,864 L.L
M01AH05 ETOXA G Etoricoxib - 60mg 60mg Tablet, film coated 369,877 L.L
B03AA02 FEOSTA G Ferrous fumarate - 200mg 200mg Tablet, film coated 9,355,300 L.L
C05CA03 DIOVENOR 600 B Diosmin - 600mg 600mg Tablet, film coated 1,089,856 L.L
C10AA07 ROSUCOR G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 487,623 L.L
J01MA14 FLOXIMOX G Moxifloxacin (HCl) - 400mg 400mg Tablet, film coated 1,062,276 L.L
L04AA42 MAYZENT B Siponimod - 0.25mg 0.25mg Tablet, film coated 15,102,158 L.L
M01AH05 ETOXIB G Etoricoxib - 60mg 60mg Tablet, film coated 1,217,521 L.L
C10AA07 ROSUPHAR G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 487,623 L.L
L04AA42 MAYZENT B Siponimod - 0.25mg 0.25mg Tablet, film coated 124,258,444 L.L
M01AH05 ARCOXIA B Etoricoxib - 90mg 90mg Tablet, film coated 2,119,240 L.L
C10AA07 ROSUVAS G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 450,187 L.L
L04AA42 MAYZENT B Siponimod - 2mg 2mg Tablet, film coated 124,258,444 L.L
M01AH05 ARTRIX 90 G Etoricoxib - 90mg 90mg Tablet, film coated 1,228,656 L.L
A02BC04 RABEC G Rabeprazole (sodium) - 20mg 20mg Tablet, film coated 212,327 L.L
J01MA14 QUINOMOX G Moxifloxacin (HCl) - 400mg 400mg Tablet, film coated 912,469 L.L
M01AH05 CLINTON G Etoricoxib - 90mg 90mg Tablet, film coated 454,219 L.L
C02KX04 OPSUMIT B Macitentan - 10mg 10mg Tablet, film coated L.L
C10AA07 ROXARDIO G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 720,525 L.L
M01AH05 CLINTON G Etoricoxib - 90mg 90mg Tablet, film coated 1,280,682 L.L
    ...
    25
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025